|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In the first half of 2017, Roche’s (RHHBY) Xolair reported revenues of CHF 866.0 million, which is a 17.0% rise on a YoY (year-over-year) basis.
Today we’re going to take a look at the well-established Illumina Inc (NASDAQ:ILMN). The company’s stock saw a double-digit share price rise of over 10% in the past couple ofRead More...
In the first half of 2017, Roche’s (RHHBY) Rituxan/MabThera reported revenues of CHF 3.8 billion, which is a 3.0% rise on a YoY basis.